ABSTRACT: Introduction: Myofiber type grouping is a histological hallmark of age-related motor unit remodeling. Despite the accepted concept that denervation-reinnervation events lead to myofiber type grouping, the completeness of those conversions remains unknown. Methods: Type I myofiber grouping was assessed in vastus lateralis biopsies from Young (26 6 4 years; n 5 27) and Older (66 6 4 years; n 5 91) adults. Grouped and ungrouped type I myofibers were evaluated for phenotypic differences. Results: Higher type I grouping in Older versus Young was driven by more myofibers per group (i.e., larger group size) (P < 0.05). In Older only, grouped type I myofibers displayed larger cross-sectional area, more myonuclei, lower capillary supply, and more sarco(endo)plasmic reticulum calcium ATPase I (SERCA I) expression (P < 0.05) than ungrouped type I myofibers. Discussion: Grouped type I myofibers retain type II characteristics suggesting that conversion during denervation-reinnervation events is either progressive or incomplete.
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Human aging is associated with gradual declines in skeletal muscle mass, a process commonly termed sarcopenia. 1 This aging muscle atrophy is predominantly attributed to a loss of total myofiber number consequent to central and/or peripheral denervation combined with type II myofiber atrophy. [2] [3] [4] A denervated myofiber follows 1 of 2 fates: death, or reinnervation by the branching axon of a viable motor neuron nearby. The latter leads to motor unit reorganization with an increase in motor unit size, [5] [6] [7] which is revealed histopathologically as abnormal grouping of myofibers expressing the same myosin heavy chain (MHC) isoform. 8, 9 Such myofiber type grouping, particularly type I grouping within the human vastus lateralis, has become a hallmark of motor unit reorganization during aging and neurogenic atrophy.
Although the notion that myofiber type grouping increases as humans age is widely accepted, there is not a consensus methodology to quantitatively assess the extent of myofiber grouping. Traditional methods to assess myofiber type grouping include runs, enclosed fibers, points-sommets, codispersion indices, and distance methods 10 ; while more recent methods include variations of the aforementioned techniques or arbitrary thresholds for contiguous fibers of the same type. 11 Despite the numerous descriptions and derivations of myofiber type grouping, attempts to quantify the degree of grouping within a specimen are largely tests of nonrandomness based on the assumption that the spatial distribution of myofiber types in healthy tissue is completely random. 10 However, myofiber type distribution clearly influences the spatial arrangement of myofiber types in crosssection. For example, a biopsy specimen containing 60% type I myofibers will display more enclosed and contiguous type I myofibers by random chance than a specimen with only 30% type I myofibers. With this in mind, we developed a modified method to quantify the number and size of abnormal myofiber groups that takes into account myofiber type distribution, with the goal of more effectively comparing widely divergent specimens.
In addition to the current lack of quantitative data regarding the degree of type I myofiber grouping in aged human skeletal muscle, it remains completely unknown whether grouped and ungrouped type I myofibers are phenotypically the same. Although they both express the MHC I isoform, it has long been known that motor neuron impulse patterns determine myofiber MHC expression. 12, 13 Thus, MHC I expression may only be reflective of their low threshold motor unit innervation status. Because denervated myofibers can undergo reinnervation by both low (innervate type I myofibers) and high (innervate type II myofibers) threshold neighboring motor neurons, 14 a portion of grouped MHC type I myofibers will have experienced a switch from a high threshold type II motor unit to a low threshold type I motor unit. In such cases, it is currently not known if the denervation-reinnervation process only changes the MHC isoform expression or results in a complete phenotypic myofiber type switch.
Using our new model to identify grouped type I myofibers, we quantified the effects of aging on abnormal type I myofiber grouping. Furthermore, we performed a phenotypic analysis of grouped type I myofibers, using ungrouped type I and type II myofibers as comparators. We hypothesized that grouped type I myofibers, specifically in Older adults with pathological grouping, would display a phenotypic resemblance to type II myofibers, indicating incomplete myofiber type switching among grouped type I myofibers which were previously type II.
MATERIALS AND METHODS
Human Subjects. All myofiber type grouping and phenotyping assessments were accomplished by using available vastus lateralis muscle biopsy specimens collected from 20-to 35-year-old adults (Young: 26 6 4 years, n 5 27; 12F, 15M) and 60-to 75-year-old adults (Older: 66 6 4 years, n 5 91; 41F, 50M) over 2 consecutive, 5-year award periods of R01AG017896. Participants were recruited from the Birmingham, Alabama, metropolitan area and gave written, informed consent allowing their samples and data to be used for future research as approved by the University of Alabama at Birmingham (UAB) Institutional Review Board. All subjects completed health history and physical activity questionnaires, and older adults underwent a physical exam during screening. The young cohort was recruited only during the first 5-year period, whereas the older adults were recruited in both periods. Identical inclusion/exclusion criteria were used in recruitment of the older adults across the 2 periods. Briefly, individuals were excluded for: lidocaine allergy, prescription anticoagulants, exogenous testosterone or other pharmacological interventions thought to influence muscle mass, acute illness or active infection, chronic end-stage disease, uncontrolled hypertension, unstable or exercise-induced angina pectoris or myocardial ischemia, diabetes mellitus, musculoskeletal disorder or any known contraindication to exercise training or testing. Additionally, subjects who were currently adherent to a weight reduction diet, had a body mass index >30, or had performed regular resistance training during the previous 3 years were excluded. 15, 16 Skeletal Muscle Biopsy and Tissue Preparation. Muscle tissue samples were previously collected by percutaneous needle biopsy of the right vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5-mm Bergstrom-type biopsy needle with suction. Samples were prepared for immunohistochemistry as previously described. 17 Biopsies were performed in the Clinical Research Unit of the UAB Center for Clinical and Translational Science.
Immunohistochemistry and Type I Myofiber Grouping.
We quantified the prevalence of type I grouping after first determining myofiber type distribution (I, IIa, IIx) by means of MHC isoform immunofluorescence methods routinely used in our laboratory 17, 18 To determine the degree of abnormal type I myofiber grouping, we developed the following quantitative method. First, we found the expected mean (M) number of like myofibers touching a given type I myofiber by multiplying the total number (n) of myofibers touching a given myofiber by the type I myofiber percent distribution (p) as a decimal; such that M 5 np. We then determined the standard deviation (SD) around M, which equaled the square root of npq, where q is 1-p. To qualify as a myofiber group, the number of like myofibers touching a given type I myofiber (X) was required to be equal to or greater than M1SD for at least 2 contiguous myofibers in the core of a group; such that X1 M11SD1 and X2 M21SD2. This process ensured that the core myofibers of a group exceed the normal probability of adjacent like myofibers. Once 2 contiguous core myofibers were identified, all subsequent contiguous type I myofibers were counted as part of the group. Myofibers were not considered contiguous if separated by clearly visible fascicle borders (i.e., perimysium) Supplementary Fig.  S1 is available online.
By factoring type I distribution into the determination of core fibers, this new approach appropriately makes it more difficult to classify type I myofibers as "abnormally grouped" in samples with a high overall type I distribution; however, it does not completely eliminate the influence of myofiber type distribution. For example, with the approach used here, correlations between type I distribution and the amount of type I grouping are modest but statistically significant (R 2 5 0.58 overall, and R 2 5 0.35 for the subset of Older with < 50% type I grouping). Thus, across a wide range between subjects, individual percent type I distribution may account for up to 58% of the variance in type I grouping prevalence.
We also performed immunofluorescent detection of myonuclei, satellite cells, capillaries, and sarco/endoplasmic reticulum Ca 21 ATPase (SERCA) expression. All immunohistochemistry was performed on fresh-frozen 6-lm thick serial cryo-sections and each stain included detection of MHC I. Unless otherwise noted, all primary and secondary antibody dilutions were made in 1% goat serum and were incubated at 37 8C for 30 min, all blocking steps were performed for 20 min at room temperature before primary antibody incubations and consisted of 5% goat serum, and each step was separated by a 3 3 5 min 1 3 phosphatebuffered saline (PBS) wash. Upon completion of each stain, tissue sections were dried, mounted, cover slipped and stored at -20 8C until analysis.
To detect myofiber type-specific satellite cells and myonuclei, sections were first fixed in ice cold acetone for 3 min at room temperature then washed 3 3 3 min in 1 3 PBS and incubated in 3% H 2 O 2 (in 1 3 PBS) for 10 min at room temperature. Following another PBS wash, samples were blocked in 2.5% horse serum for 1 hr at room temperature and incubated overnight in paired box 7 (PAX7) primary antibody (1:100 in 2.5% horse serum; Developmental Studies Hybridoma Bank) at 4 8C. Samples were then incubated in a biotinylated goat-anti-mouse (GAM) secondary (1:1,000 in 2.5% horse serum; Jackson Labs, 115-065-003) for 1 h at room temperature, washed, and incubated in streptavidin horse radish peroxidase (1:100 in 1 3 PBS; ThermoFIsher T20932) for 1 h at room temperature. Lastly, samples were washed, incubated in tyramide conjugated Alexa Fluor 488 (1:200 in amplification buffer; ThermoFisher T20932) for 20 min at room temperature, and an anti-MHC I/laminin immunostain and Hoechst DNA counterstain were performed as described previously. 17, 19 Myofiber type-specific capillaries were visualized by incubating cryo-sections in fluorescein isothiocyanate-conjugated Ulex europaeus agglutinin (UEA-I; 1:100 in 1 3 PBS; SigmaAdrich L9006) at room temperature for 45 min without a previous fixative step. Next, the sections were blocked and subsequently incubated in anti-MHC I primary (1:100; Leica NCL-MHCs) and Alexa Fluor 594-GAM secondary Statistical Analysis. All biopsy specimens were fiber typed, however, because the majority of specimens (Young: n 5 27/27; Older: n 5 66/91) were obtained from previously completed clinical trials, sample sizes varied for each assessment based on sample availability. Sample sizes are as follows: Immunohistological differences between Young and Older subjects were compared by means of independent 2-tailed ttests. Within group myofiber population (grouped type I, ungrouped type I, and type II) differences were determined using 1-way analyses of variance. Significant main effects were followed up by Fisher's least significant difference tests post hoc. Ages of human subjects are reported as means 6 SD; all other data are reported as means 6 SE. For all tests, P 0.05 (2-tailed) was considered statistically significant.
RESULTS
Age-Related Type I Myofiber Grouping. Normal human aging through the seventh decade of life does not appear to significantly alter myofiber type distribution (Fig. 1A) . On the other hand, there is a spatial change in myofiber distribution with aging, resulting in heightened type I myofiber grouping (Fig. 1B) . The age associated increase in type I myofiber grouping stems from an enlargement of the number of type I myofibers per group (i.e., group size) (Fig. 1C) rather than the number of abnormal myofiber groups (Fig. 1D) .
Grouped Type I Myofiber CSA, Nuclei, and Satellite Cells. As expected, Older displayed type II myofiber atrophy (Fig. 2A) ; however, surprisingly Older grouped type I myofibers were on average 576 mm 2 larger than their ungrouped counterparts ( Fig. 2A) . The enlarged CSA of Older grouped type I myofibers was apparently supported by myonuclear addition (Fig. 2B) , which maintained a constant myonuclear domain among Older type I myofibers (Fig. 2C) . Older type II myonuclear domain, however, was lower than Young, concomitant with the type II myofiber atrophy because type II myonuclear content did not differ by age. There were also no age-related differences in PAX7 1 nuclei associated with any of the myofiber types, suggesting that the resident muscle stem cell population is preserved with age ( Fig. 2D) and, therefore, capable of supporting myonuclear addition. There were no CSA, myonuclear, or satellite cell differences among any of the myofiber types in Young.
Grouped Type I Myofiber Capillary Supply. In Figure  3A , Young displays the well-documented higher capillary supply of oxidative, fatigue-resistant type I myofibers compared with the lower capillary supply of type II myofibers. Grouped and ungrouped type I myofibers showed the same capillary supply in Young. On the other hand, among Older, the capillary supply of grouped type I myofibers was substantially lower than in ungrouped type I fibers and resembled type II myofiber capillary supply.
Grouped Type I Myofiber SERCA I Expression. The proportion of hybrid myofibers expressing both SERCA I and MHC I was higher in Older compared with Young (Fig. 4A) . The aging effect was driven by greater co-expression among grouped (Older: 19 6 2 vs. Young: 6 6 1%; P < 0.05) rather than ungrouped (Older: 5 6 1% vs. Young: 8 6 1%) MHC type I myofibers when normalized to total number of type I myofibers. Within the total pool of SERCA I 1 / MHC I 1 myofibers, nearly 75% of Older hybrids were located among grouped type I myofibers compared with just 37% in Young (Fig. 4B) .
Grouped versus Ungrouped Type I Myofiber Phenotype
is Associated with Grouping Prevalence. Despite the well-accepted notion that aging results in myofiber type grouping, the inter-individual heterogeneity in the proportion of type I myofibers grouped was quite large among Older individuals in this study. In an effort to explore phenotypic differences along the grouping prevalence spectrum, we applied a K-means cluster analysis to the Older data to derive 3 distinct clusters of individuals, which displayed low (Low: n 5 31; 14F, 17M), moderate (Mod: n 5 38; 16F, 22M), and high (High: n 5 22; 11F, 11M) levels of type I myofiber grouping (Fig. 5A) . Using Young as a healthy reference, the Older type I grouped versus ungrouped differences in CSA (Fig. 5B) , capillary supply (Fig. 5C) , and MHC I 1 / SERCA I 1 co-expression ( Fig. 5D / E) were assessed. Interestingly, Low was no different than Young on any of the measures, whereas Mod and High grouped type I myofibers displayed similarly lower capillary supply and higher numbers of SERCA I 1 / MHC I 1 hybrids compared with both Young and Low. Grouped versus ungrouped type I myofiber CSA disparities presented in a step-wise pattern with Mod displaying a greater difference than Young and Low, while High displayed the largest difference which was greater than Young, Low, and Mod.
DISCUSSION
The current work provides a quantitative assessment of type I myofiber grouping that confirms the expected aging-associated increase in grouping. Additionally, we have conducted a detailed phenotypic characterization of grouped type I myofibers in aged humans. The data indicate that grouped type I myofibers possess features of type II myofibers including recruitment-dependent hypertrophy and myonuclear addition, lower capillary supply, and SERCA I expression. Furthermore, the phenotypic differences between grouped and ungrouped type I myofibers increase as grouping prevalence increases. These findings strongly suggest myofiber type switching resulting from denervation-reinnervation is not complete, as several characteristics of the original myofiber type (II) appear to be retained.
Aging has long been associated with the appearance of myofiber type grouping in histopathological analysis. 8, 9, 20, 21 Based on our statistical model, a small amount of type I grouping (20%) is detected in Young healthy muscle and may be considered "normal," particularly because there are no phenotypic differences between grouped and ungrouped type I myofibers in Young (i.e., not indicative of pathology). Therefore, results in Young here may serve as a valuable reference point in future studies of aging and disease. It is noteworthy that the age-related type I grouping found here was not associated with an aging difference in myofiber type distribution. Based on previously published data, similar type distribution between young adults and 60-to 75-year-old adults is common. 3, 4, 22, 23 This suggests that denervation-reinnervation and myofiber type conversion events are bidirectional (MHC type II to type I, and vice versa) and occur at similar rates. We focused on quantifying and characterizing type I grouping in part because type II fibers comprise 65% of the total distribution in human vastus lateralis, which would make an analysis of "abnormal grouping" quite challenging.
This work characterizes in detail grouped versus ungrouped type I myofibers, revealing type IIlike features among grouped type I fibers in the Older cohort. The larger CSA among grouped type I myofibers in Older suggests that, despite belonging to similar low threshold motor units, grouped and ungrouped type I myofibers displayed divergent hypertrophic responses to recruitment. We 15 and others 24 have shown a similar divergence in hypertrophic response to recruitment (i.e., resistance exercise training [RT] ) between type II and type I myofibers in healthy adults. In our hands, type II myofiber hypertrophy following highintensity RT is approximately twice that of type I myofibers regardless of age. 15 Furthermore, in instances where myofiber hypertrophy is substantial following RT, particularly in type II myofibers, hypertrophy is accompanied by satellite cell-mediated myonuclear addition presumably to limit expansion of myonuclear domain size. 16, [24] [25] [26] Here, we show that grouped type I myofibers appear to support their large CSA by means of myonuclear addition in a manner similar to resistance trained type II myofibers. We, therefore, speculate that type II myofibers which have converted to grouped type I myofibers by means of denervation-reinnervation retain their inherently greater hypertrophic potential even after MHC I conversion has taken place. Upon reinnervation-induced conversion, former type II myofibers would experience far more frequent recruitment (now as part of low threshold motor units) which may serve as the growth stimulus resulting in hypertrophy and myonuclear addition. Interestingly, the number of capillary contacts per myofiber is another indicator of a type II-like phenotype among grouped type I myofibers in Older adults.
Regarding SERCA isoform expression, not only did Older have more MHC I 1 / SERCA 1 1 hybrids than Young, the overwhelming majority of Older hybrid myofibers were found among grouped type I myofibers. The expression pattern of SERCA in grouped type I myofibers suggests that MHC and SERCA isoform expression are not coupled/proportionate during denervation-reinnervation myofiber type switching. In fact, there is evidence supporting this concept in the context of denervation as Talmadge et al. 27 have shown MHC and SERCA transitions occur independently after human spinal cord injury. Because myofiber type conversions are likely bidirectional during the dynamic processes of denervation-reinnervation, one might also expect some MHC type II myofibers to express SERCA 2a, suggesting they were once pure type I myofibers. We did not test this possibility here because of the aforementioned difficulty of quantifying abnormal type II myofiber grouping in a predominantly type II muscle.
We noted a considerable amount of interindividual heterogeneity in type I myofiber grouping prevalence (range: 5-99%) among Older individuals, which led to the use of K-means cluster analysis. In doing so, we identified a Low cluster among Older adults that did not differ from young on any of the grouped versus ungrouped type I myofiber analyses. On the other hand, the Mod and High clusters of Older adults displayed a progressive expansion of differences between grouped and ungrouped type I myofibers, suggestive of a higher presence of partially converted type II myofibers among the grouped type I myofibers.
Although type I myofiber grouping is accepted as a biomarker of denervation-reinnervation events, whether type I myofiber grouping prevalence is degenerative or advantageous is unclear. For example, if the rate of denervation is constant with advancing age, then higher type I myofiber grouping prevalence is indicative of higher reinnervative capacity/efficiency (i.e., advantageous).
On the other hand, if reinnervation rate is fairly constant, the higher type I myofiber grouping prevalence would be indicative of higher levels of denervation (i.e., degenerative). Therefore, our data suggest that either Mod and High experience similar denervation to Low but reinnervate with, respectively, higher efficiency (preserving more myofibers), or that Mod and High display, respectively, higher rates of denervation-reinnervation events (ultimately losing more myofibers). Either scenario apparently leads to more type II myofibers in the grouped type I myofiber pool, with type I MHC expression being the only characteristic of fiber type conversion identified here.
In conclusion, altogether our findings indicate that heightened type I myofiber grouping in Older is driven by an increased number of myofibers per abnormal group and that, as grouping prevalence increases among Older individuals, the presence of type I myofibers displaying type II phenotypic characteristics increases within those groups. Therefore, reinnervation-induced type II myofiber conversion to type I within myofiber groups does not appear to be immediate/complete. In future studies, functional characterizations of older individuals displaying varying amounts of type I myofiber grouping may be helpful in determining whether myofiber grouping is advantageous or deleterious.
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